Chalbot Sonia, Morfin Robert
Laboratoire de Biotechnologie, EA 3199, Conservatoire National des Arts et Metiers, 2 rue Conté, 75003 Paris, France.
Steroids. 2005 Apr;70(4):319-26. doi: 10.1016/j.steroids.2004.12.004.
Both dehydroepiandrosterone (DHEA) and epiandrosterone (EpiA) are substrate for cytochrome P450 species and enzymes that produce 7alpha- and 7beta-hydroxylated metabolites in the brain and other organs. In contrast to DHEA and EpiA, the 7-hydroxylated derivatives were shown to mediate neuroprotection, and 7beta-hydroxy-EpiA was the most potent. The suggested use of any of these steroids as drugs administered per os for neuroprotection requires the assessment of their metabolism in the human intestine and liver. To achieve this, we produced radio-labeled 7alpha-hydroxy-DHEA, 7beta-hydroxy-DHEA, 7alpha-hydroxy-EpiA and 7beta-hydroxy-EpiA that were used as substrates in incubations with human intestine microsomes supplemented with reduced or oxidized cofactors. Identity of the radio-labeled metabolites obtained was determined by gas chromatography/mass spectrometry after comparison with authentic steroid references. The proportions of metabolites produced resulted from their radioactivity contents. The only metabolite obtained with DHEA, EpiA, 7alpha-hydroxy-DHEA and 7beta-hydroxy-DHEA substrates was its 17beta-reduced derivative, thus inferring the presence of 17beta-hydroxysteroid oxidoreductases in the human intestine microsomes. In addition to the 7alpha-hydroxy-EpiA and 7beta-hydroxy-EpiA substrates, their 17beta-reduced metabolites were obtained with 7beta-hydroxy-EpiA and 7alpha-hydroxy-EpiA, respectively. The identity of the enzyme responsible for the 7alpha-hydroxy-EpiA/7beta-hydroxy-EpiA inter-conversion is unknown. The incubation conditions used produced these metabolites in low but significant yields that suggest their presence in the portal blood before access to the liver.
脱氢表雄酮(DHEA)和表雄酮(EpiA)都是细胞色素P450家族成员以及在大脑和其他器官中产生7α-和7β-羟基化代谢产物的酶的底物。与DHEA和EpiA不同,7-羟基化衍生物已被证明具有神经保护作用,其中7β-羟基-EpiA的作用最强。若建议将这些甾体中的任何一种作为口服神经保护药物使用,则需要评估它们在人体肠道和肝脏中的代谢情况。为此,我们制备了放射性标记的7α-羟基-DHEA、7β-羟基-DHEA、7α-羟基-EpiA和7β-羟基-EpiA,将其作为底物与添加了还原型或氧化型辅因子的人肠道微粒体进行孵育。通过与甾体标准品比较,利用气相色谱/质谱法确定所得放射性标记代谢产物的身份。所产生代谢产物的比例由其放射性含量决定。以DHEA、EpiA、7α-羟基-DHEA和7β-羟基-DHEA为底物时,唯一得到的代谢产物是其17β-还原衍生物,由此推断人肠道微粒体中存在17β-羟基甾体氧化还原酶。除了7α-羟基-EpiA和7β-羟基-EpiA底物外,分别以7β-羟基-EpiA和7α-羟基-EpiA为底物时还得到了它们的17β-还原代谢产物。负责7α-羟基-EpiA/7β-羟基-EpiA相互转化的酶的身份尚不清楚。所用的孵育条件产生这些代谢产物的产率较低但很显著,这表明它们在进入肝脏之前存在于门静脉血中。